Parkinson research grant · Biotech
Alchemab receives $595,000 grant for Parkinson’s antibody research
The Michael J. Fox Foundation funds research into antibodies identified in people resilient to Parkinson’s disease.
Alchemab Therapeutics announced a $595,000 grant from The Michael J. Fox Foundation for Parkinson’s Research on 6 June 2024. The award, made through the foundation’s Parkinson’s Disease Therapeutics Pipeline Program, funds research performed at Alchemab.
The company is investigating antibodies associated with resilience to Parkinson’s disease and their effects on prostaglandin biology. Its programme combines analysis of patient samples with computational and laboratory research to assess potential treatment approaches.
Use of funds
Develop resilient-patient antibody programme for Parkinson disease
Funding history
Parkinson research grant · This round$595K
Biomedical Catalyst grant£1.7MSeries A£60MBiomedical Catalyst grantUndisclosed